Boston Scientific Corporation (BSX) Shares are Up 1.17%

Boston Scientific Corporation (BSX) : Traders are bullish on Boston Scientific Corporation (BSX) as it has outperformed the S&P 500 by a wide margin of 0.66% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 1.2%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.17% in the last 1 week, and is up 1.05% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

Boston Scientific Corporation is up 8.05% in the last 3-month period. Year-to-Date the stock performance stands at 31.07%. The stock has recorded a 20-day Moving Average of 0.72% and the 50-Day Moving Average is 2.72%.


Boston Scientific Corporation (NYSE:BSX): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $23.92 and $23.88 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $24.18. The buying momentum continued till the end and the stock did not give up its gains. It closed at $24.17, notching a gain of 0.88% for the day. The total traded volume was 4,712,158 . The stock had closed at $23.96 on the previous day.

Also, Brokerage firm Citigroup maintains its rating on Boston Scientific Corporation (NYSE:BSX). As per the latest information, the brokerage house raises the price target to $28 per share from a prior target of $26. The shares have been rated Buy. The rating by the firm was issued on August 3, 2016.

Boston Scientific Corporation develops, manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology, which includes Drug-Eluting Coronary Stent Systems, Intravascular Imaging devised and Coronary Technology products, such as guide wires, guide catheters, and balloon catheters, among others; Peripheral Interventions (PI), which include stents, balloon catheters, wires, peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM), which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP), which include steerable RF ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories; Endoscopy, which includes Spyglass System, WallFlex Colonic Stents, Resolution Clip, and Expect Aspiration Needle, among others; Urology and Womens Health, and Neuromodulation.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.